Standard BioTools
LAB
100 hedge funds and large institutions have $230M invested in Standard BioTools in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 23 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
13% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $1.01M
6% less funds holding
Funds holding: 106 → 100 (-6)
25% less capital invested
Capital invested by funds: $306M → $230M (-$75.8M)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$15.1M |
| 2 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$8.17M |
| 3 |
Jennison Associates
New York
|
+$3.13M |
| 4 |
Neuberger Berman Group
New York
|
+$2.46M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$16.3M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$6.62M |
| 3 |
O
OrbiMed
New York
|
-$5.08M |
| 4 |
Goldman Sachs
New York
|
-$4.37M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$2.91M |
LAB Hedge Fund Activity: Q1 2016 in Review
100 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2016, worth a combined $230M — down 25% from $306M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LAB and 17 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 35 added.
The largest buyer was Levin Capital Strategies, opening a new position worth an estimated $15.1M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $16.3M sold.
- 100 institutional investors held Standard BioTools (LAB) as of Q1 2016, down from 106 in Q4 2015.
- Funds reported $230M of Standard BioTools stock for Q1 2016, down 25% quarter-over-quarter.
- 17 funds opened new Standard BioTools positions in Q1 2016 and 23 closed out, a net change of -6 holders.
- The largest Standard BioTools buyer in Q1 2016 was Levin Capital Strategies, an estimated $15.1M added.
- The largest Standard BioTools seller in Q1 2016 was Scopia Capital Management, an estimated $16.3M sold.
Based on aggregated 13F filings for Q1 2016.